Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea.
Department of Cardiology, Chonnam National University Hospital, Gwangju, Republic of Korea; Department of Cardiology, Chonnam National University Medical School, Gwangju, Republic of Korea.
J Am Coll Cardiol. 2021 Apr 20;77(15):1859-1870. doi: 10.1016/j.jacc.2021.02.041.
Real-world data on baseline characteristics, clinical practice, and outcomes of late presentation (12 to 48 h of symptom onset) in patients with ST-segment elevation myocardial infarction (STEMI) are limited.
This study aimed to investigate real-world features of STEMI late presenters in the contemporary percutaneous coronary intervention (PCI) era.
Of 13,707 patients from the Korea Acute Myocardial Infarction Registry-National Institutes of Health database, 5,826 consecutive patients diagnosed with STEMI within 48 h of symptom onset during 2011 to 2015 were categorized as late (12 to 48 h; n = 624) or early (<12 h; n = 5,202) presenters. Coprimary outcomes were 180-day and 3-year all-cause mortality.
Late presenters had remarkably worse clinical outcomes than early presenters (180-day mortality: 10.7% vs. 6.8%; 3-year mortality: 16.2% vs. 10.6%; both log-rank p < 0.001), whereas presentation at ≥12 h of symptom onset was not independently associated with increased mortality after STEMI. The use of invasive interventional procedures abruptly decreased from the first (<12 h) to the second (12 to 24 h) 12-h interval of symptom-to-door time ("no primary PCI strategy" increased from 4.9% to 12.4%, and "no PCI" from 2.3% to 6.6%; both p < 0.001). Mortality rates abruptly increased from the first to the second 12-h interval of symptom-to-door time (from 6.8% to 11.2% for 180-day mortality; from 10.6% to 17.3% for 3-year mortality; all p < 0.05).
Data from a nationwide prospective Korean registry reveal that inverse steep differences in the use of invasive interventional procedures and mortality rates were found between early and late presenters after STEMI. A multidisciplinary approach is required in identifying late presenters of STEMI who can benefit from invasive interventional procedures until further studied.
关于 ST 段抬高型心肌梗死(STEMI)患者发病后 12 至 48 小时就诊的基线特征、临床实践和结局的真实世界数据有限。
本研究旨在探讨当代经皮冠状动脉介入治疗(PCI)时代 STEMI 迟发患者的真实特征。
从韩国急性心肌梗死注册-美国国立卫生研究院数据库中的 13707 例患者中,将 2011 年至 2015 年期间发病后 48 小时内诊断为 STEMI 的连续 5826 例患者分为迟发(12 至 48 小时;n=624)或早发(<12 小时;n=5202)组。主要复合结局为 180 天和 3 年全因死亡率。
迟发组患者临床结局明显差于早发组(180 天死亡率:10.7%比 6.8%;3 年死亡率:16.2%比 10.6%;log-rank p均<0.001),而症状发作至就诊时间≥12 小时与 STEMI 后死亡率增加无关。从症状发作至就诊时间的第一个(<12 小时)12 小时间隔到第二个(12 至 24 小时)12 小时间隔,侵入性介入治疗的使用率急剧下降(“无直接 PCI 策略”从 4.9%增至 12.4%,“无 PCI”从 2.3%增至 6.6%;均 p<0.001)。从症状发作至就诊时间的第一个 12 小时间隔到第二个 12 小时间隔,死亡率急剧增加(180 天死亡率从 6.8%增至 11.2%;3 年死亡率从 10.6%增至 17.3%;均 p<0.05)。
来自全国前瞻性韩国注册研究的数据显示,STEMI 迟发患者与早发患者相比,侵入性介入治疗的使用率和死亡率呈明显反向陡峭差异。需要采取多学科方法来确定 STEMI 迟发患者,直到进一步研究,以确定他们是否可以从侵入性介入治疗中获益。